DeepMed Research

Innovent Biologics (Suzhou) Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Phase 1

Recruiting

Conditions: Healthy Participants
Asthma

Interventions: Drug: Placebo
Drug: IBI3002

First Posted Date: 2024-01-19

Last Posted Date: 2024-03-07

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 52

Registration Number: NCT06213844

Locations: 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: IBI3004

First Posted Date: 2024-01-10

Last Posted Date: 2025-03-25

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 106

Registration Number: NCT06198426

Locations: 🇦🇺
Liverpool Hospital, Sydney, New South Wales, Australia
🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇨🇳
Jiang Su Province Hospital, Nanjing, Jiangsu, China

and more 2 locations

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Phase 1

Active, not recruiting

Conditions: Healthy Participants
Atopic Dermatitis Patients

Interventions: Drug: Placebo for MAD
Drug: Dupilumab for MAD
Drug: Placebo for SAD
Drug: IBI356 for SAD
Drug: IBI356 for MAD

First Posted Date: 2024-01-05

Last Posted Date: 2025-03-14

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 99

Registration Number: NCT06193434

Locations: 🇨🇳
Shanghai Skin Disease Hospital, Shanghai, Shanghai, China

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes
Obesity

Interventions: Drug: IBI362
Drug: Semaglutide

First Posted Date: 2023-12-28

Last Posted Date: 2025-01-15

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 349

Registration Number: NCT06184568

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Phase 1

Recruiting

Conditions: Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions: Biological: IBI133

First Posted Date: 2023-12-14

Last Posted Date: 2024-02-06

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 120

Registration Number: NCT06170190

Locations: 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia

A Study of IBI362 9 mg in Chinese Adults With Obesity

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Placebo
Drug: IBI362

First Posted Date: 2023-12-11

Last Posted Date: 2024-08-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 462

Registration Number: NCT06164873

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Phase 3

Active, not recruiting

Conditions: Thyroid Eye Disease, TED

Interventions: Drug: IBI311

First Posted Date: 2023-11-13

Last Posted Date: 2024-12-13

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 91

Registration Number: NCT06126783

Locations: 🇨🇳
Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Safety and Tolerance Study of IBI355 in Health Volunteers

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: placebo
Drug: IBI355

First Posted Date: 2023-10-31

Last Posted Date: 2024-10-21

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 53

Registration Number: NCT06110338

Locations: 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: IBI3003

First Posted Date: 2023-10-13

Last Posted Date: 2024-12-13

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 116

Registration Number: NCT06083207

Locations: 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
St Vincent's Hospital, Melbourne, Victoria, Australia
🇦🇺
Wollongong Private Hospital, Wollongong, New South Wales, Australia

and more 10 locations

A Study of IBI363 in Subjects With Advanced Melanoma

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Biological: IBI363

First Posted Date: 2023-10-13

Last Posted Date: 2025-05-16

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 150

Registration Number: NCT06081920

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
The Third people's hospital of Zhengzhou, Zhengzhou, Henan, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy